Form 4: Cocrystal Pharma Director Boosts Stake

Cocrystal Pharma Director Phillip Frost, MD, increased his indirect beneficial ownership by purchasing 20,000 shares of common stock.

Summary

• Phillip Frost, MD, a Director and 10% Owner of Cocrystal Pharma, Inc. (COCP), acquired 20,000 shares of common stock.
• The shares were purchased on February 24, 2026, at a weighted average price of $0.9976 per share, with transactions ranging from $0.98 to $1.00.
• The acquisition was made indirectly through Frost Gamma Investments Trust, of which Dr. Frost is the trustee.
• Following this transaction, Frost Gamma Investments Trust beneficially owns 1,908,551 shares of common stock.
• Additionally, Dr. Frost directly holds 27,100 shares, which include common stock issuable upon vesting of restricted stock units.
• Dr. Frost disclaims beneficial ownership of securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest.
• The filing also notes that Dr. Frost disclaims beneficial ownership of securities held by OPKO Health, Inc., where he is Chairman and CEO, as he does not hold voting and investment control over those securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. Insider buying, especially by a director and significant owner, typically signals confidence in the company's future, although the transaction size relative to total holdings should be considered.

Positives

• Insider buying by a Director and 10% Owner, Phillip Frost, MD, signals confidence in the company's future prospects.
• The purchase of 20,000 shares at an average price of $0.9976 demonstrates a direct financial commitment from a key insider.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook; it solely reports an insider transaction.

Management Comments

• Phillip Frost, MD, through Frost Gamma Investments Trust, acquired 20,000 shares of common stock, indicating a personal investment decision.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director and significant shareholder like Phillip Frost, MD, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This can sometimes precede periods of increased investor interest in the biotechnology sector, especially for companies like Cocrystal Pharma focused on antiviral drug development.

Related Party Transactions

• The acquired shares are held by Frost Gamma Investments Trust, where Phillip Frost, MD, is the trustee and Frost Gamma L.P. is the sole beneficiary. Dr. Frost is one of two limited partners of Frost Gamma L.P., and is the sole stockholder of Frost Gamma, Inc. (general partner) and Frost-Nevada Corporation (sole stockholder of Frost Gamma, Inc.).
• Phillip Frost, MD, disclaims beneficial ownership of securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest.
• Phillip Frost, MD, disclaims beneficial ownership of securities held by OPKO Health, Inc., where he is Chairman and CEO, as he does not hold voting and investment control over those securities.

Stakeholder Impact

• Shareholders may perceive the insider purchase as a positive indicator of management's confidence in the company's valuation and future prospects, potentially leading to increased investor interest.
• The transaction reinforces the alignment of interests between a key director and existing shareholders.

Key Dates

Recommendation

The insider purchase by a Director and 10% Owner, Phillip Frost, MD, suggests a strong belief in the company's value proposition. Such a move by a well-informed insider often precedes positive developments or indicates that the stock is currently undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Trading, Form 4, Stock Purchase, Director, 10% Owner, Biotechnology, Pharmaceuticals